CB03-154

· Shanghai Zhimeng Biopharma, Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for CB03-154, covering 2024-09-25 to 2025-11-20. Get the full timeline:

Most recent: Clinical Trial Update: An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy [Phase 2]

See pricing